
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is a biotechnology company focused on developing novel treatments for inflammatory and immune-mediated diseases. With its lead program, SL-325, showing promising results in a Phase 1 trial, and plans for a Phase 2b trial in Crohn's disease, the company is well-positioned for success. The Phase 1 data demonstrate a clean DR3 mechanism with low immunogenicity and potential for convenient quarterly dosing, setting it apart from its competitors. With a strong pipeline and potential for market differentiation, Shattuck Labs has the potential for significant revenue growth in the future, making it an attractive investment opportunity.
Bears say
Shattuck Labs is a biotechnology company with a promising lead asset, SL-325, targeting the TL1A/DR3 inflammation pathway for inflammatory bowel disease (IBD). However, with limited clinical data and a long development timeline, the company's success is dependent on the results of its upcoming clinical trials. Additionally, the company's pipeline optionality and potential for lower immunogenicity are still speculative, making this a high-risk investment.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares